Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms

Affiliations

¹ Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA; Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China. Electronic address: JCHEN106@mgh.harvard.edu.
² Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA. Electronic address: duda@steele.mgh.harvard.edu.

Comment

Jiang Chen et al. EBioMedicine. 2020 Feb.

. 2020 Feb:52:102644.

doi: 10.1016/j.ebiom.2020.102644. Epub 2020 Jan 31.

¹ Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA; Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China. Electronic address: JCHEN106@mgh.harvard.edu.
² Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA. Electronic address: duda@steele.mgh.harvard.edu.

No abstract available

Comment on

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.
Xia S, Pan Y, Liang Y, Xu J, Cai X. Xia S, et al. EBioMedicine. 2020 Jan;51:102610. doi: 10.1016/j.ebiom.2019.102610. Epub 2020 Jan 6. EBioMedicine. 2020. PMID: 31918403 Free PMC article. Review.

1. Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J Gastroenterol. 2019;25(7):789–807. - PMC - PubMed
1. Llovet J.M., Montal R., Sia D., Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. - PubMed
1. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844. - PubMed
1. Xia S., Pan Y., Liang Y., Xu J., Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51 - PMC - PubMed
1. Hernandez-Gea V., Toffanin S., Friedman S.L., Llovet J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–527. - PMC - PubMed